Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis

16 Jan 2024

Abstract excerpt

BACKGROUND: The triple negative breast cancer (TNBC) is the most malignant subtype of breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario present the mainstay in TNBC treatment, paclitaxel resistance is still a striking obstacle for cancer cure. So it is imperative to probe new therapeutic targets through illustrating the mechanisms underlying paclitaxel chemoresistance....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldose Reductase and Taurine
Share to Ferroptosis and cancer prognosis
Share to Nuclear Receptors and Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38227591
DOI: 10.1371/journal.pone.0297260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysisPMID 38227591Read ↗

Malignant cell related gene signature for patients with triple-negative breast cancer based on integrated analysis of single cell and bulk RNA sequencingSemantic proximity Read ↗

Integrated Analysis of Single-Cell and Bulk RNA-Seq Data reveals that Ferroptosis-Related Genes Mediated the Tumor Microenvironment predicts Prognosis, and guides Drug Selection in Triple-Negative Breast CancerSemantic proximity Read ↗

Deciphering the gene regulatory circuitry governing chemoresistance in Triple-Negative Breast CancerSemantic proximity Read ↗

Identification of New Chemoresistance-Associated Genes in Triple-Negative Breast Cancer by Single-Cell Transcriptomic AnalysisSemantic proximity Read ↗

Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancerSemantic proximity Read ↗

Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-SeqSemantic proximity Read ↗

The Early-Stage Triple-Negative Breast Cancer Landscape Derives a Novel Prognostic Signature and Therapeutic TargetSemantic proximity Read ↗

Molecular subtypes and precision treatment of triple-negative breast cancerSemantic proximity Read ↗

Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxelSemantic proximity Read ↗

An insight into the development of triple-negative breast cancer at transcriptome level based on single-cell sequencing technologySemantic proximity Read ↗

Integrative analysis of scRNA-seq, spatial transcriptomics, and machine learning constructs a prognostic model for Pyrotinib resistance in breast cancerSemantic proximity Read ↗

CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.